

- 1- Boland R, Verduin ML, Ruiz P. Kaplan & Sadock's synopsis of psychiatry. 12<sup>th</sup> edition, 2022.
- 2- Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 10<sup>th</sup>, edition, 2017 .
- Chapter 2- Neuropsychiatry
- Chapter 5- Quantitative and Experimental Methods in Psychiatry
- Chapter 12- Schizophrenia and Other Psychotic Disorders
- Chapter 13- Mood Disorders
- Chapter 14- Anxiety Disorders
- Chapter 15- OCD and Related Disorders
- Chapter 17- PTSD
- Chapter 27- Psychosomatic Medicine
- 3- Tasman A, Kay J, Lieberman JA, First MB, Riba MB. Psychiatry. 4<sup>th</sup> edition. 2015.
- Chapter 1- Listening to the patient (Pages 3-19)
- Chapter 5- Professional ethics and Boundaries (Pages 71-84)
- 4- Beck JS, Cognitive Behavior Therapy. 3<sup>th</sup> edition. 2021.

۵- چکیده بارگذاری شده خلاصه روان پزشکی در قانونی سایت sanjeshp.ir

۶- منشور اخلاق حرفه ای در روانپزشکی ایران، ویراست ۱۳۹۴، اول. مصوب مجمع عمومی انجمن علمی روانپزشکان ایران که در سایت انجمن در دسترس می باشد.

۷- شناسنامه و استاندارد خدمت تحریک مغناطیسی مغزی فراجمعه ای مکرر (آر تی ام اس) ۱۳۹۹ از مستان دبیرخانه شورای راهبردی تدوین راهنماهای سلامت- معاونت درمان- وزارت و درمان، بهداشت آموزش پزشکی

۸- راهنمای بالینی مدیریت اختلال دو قطبی بزرگسالان ایران (درمان های دارویی و ابزاری). ۱۳۹۹ از مستان.

دبیرخانه شورای راهبردی تدوین راهنماهای بالینی- معاونت درمان وزارت بهداشت درمان آموزش پزشکی  
۹- مجموعه ۵۰ مقاله منتخب روانپزشکی به شرح زیر

- 1 Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World psychiatry. 2022;21(2):295-307.
2. Lu Z, Sun Y, Zhang Y, Chen Y, Guo L, Liao Y, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Translational psychiatry. 2022;12(1):1-14.
3. Rubio JM, Schoretsanis G, John M, Tiihonen J, Taipale H, Guinart D, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. The Lancet Psychiatry.

2020;7(9):749-61.

4. Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in

people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or

attenuating factors. *World psychiatry*. 2022;21(2):248-71.

5. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with

multi-episode schizophrenia: a systematic review and network meta-analysis. *The Lancet*. 2019;394(10202):939-51.

6. Bighelli I, Rodolico A, García-Mieres H, Pitschel-Walz G, Hansen W-P, Schneider-Thoma J, et al.

Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic

review and network meta-analysis. *The Lancet Psychiatry*. 2021;8(11):969-80.

7. Hasan A, von Keller R, Friemel CM, Hall W, Schneider M, Koethe D, et al. Cannabis use and

psychosis: a review of reviews. *European archives of psychiatry and clinical neuroscience*. 2020;270(4):403-12.

8. Sharma V, Sharma P, Sharma S. Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice. *Expert review of*

*neurotherapeutics*. 2020;20(4):373-83.

9. Schiweck C, Arteaga-Henriquez G, Aichholzer M, Thanarajah SE, Vargas-Cáceres S, Matura S, et

al. Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis. *Neuroscience & Biobehavioral Reviews*. 2021;124:100-23.

10. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for

Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018

guidelines for the management of patients with bipolar disorder. *Bipolar disorders*.

2018;20(2):97-170.

11. Excellence NIHC. Depression in adults: treatment and management. NICE Guideline: Short

Version Draft for Second Consultation. 2018.

12. Pearce M, Garcia L, Abbas A, Strain T, Schuch FB, Golubic R, et al. Association Between Physical

Activity and Risk of Depression: A Systematic Review and Meta-analysis. *JAMA psychiatry*. 2022.

13. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin

theory of depression: a systematic umbrella review of the evidence. *Molecular psychiatry*. 2022:1-14.

14. Miller JN, Black DW. Bipolar disorder and suicide: a review. *Current psychiatry reports*. 2020;22(2):1-10.

15. Trisha C, Kamyar K, Yatham LN. Treatment of Mixed Features in Bipolar Disorder: an Updated View. *Current Psychiatry Reports*. 2020;22(3).
16. Garakani A, Murrrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. *Frontiers in psychiatry*. 2020;1412.
17. Sharma E, Sharma LP, Balachander S, Lin B, Manohar H, Khanna P, et al. Comorbidities in Obsessive-Compulsive Disorder Across the Lifespan: A Systematic Review and Meta-Analysis. *Frontiers in psychiatry*. 2021;12.
18. Kayser RR. Pharmacotherapy for treatment-resistant obsessive-compulsive disorder. *The Journal of clinical psychiatry*. 2020;81(5):14428.
19. Rasmussen AR, Parnas J. What is obsession? Differentiating obsessive-compulsive disorder and the schizophrenia spectrum. *Schizophrenia Research*. 2022;243:1-8.
20. Huang Z-D, Zhao Y-F, Li S, Gu H-Y, Lin L-L, Yang Z-Y, et al. Comparative efficacy and acceptability of pharmaceutical management for adults with post-traumatic stress disorder: A systematic review and meta-analysis. *Frontiers in pharmacology*. 2020;11:559.
21. Collaborators GMD. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Psychiatry*. 2022;9(2):137-50.
22. Wagner-Skacel J, Matzer F, Kohlhammer-Dohr A, Dalkner N, Jauk E. Assessment of personality functioning in psychosomatic medicine. *Wiener klinische Wochenschrift*. 2022:1-9.
23. Aybek S, Perez DL. Diagnosis and management of functional neurological disorder. *bmj*. 2022;376.
24. Gilmour GS, Nielsen G, Teodoro T, Yogarajah M, Coebergh JA, Dilley MD, et al. Management of functional neurological disorder. *Journal of Neurology*. 2020;267(7):2164-72.
25. Hausteiner-Wiehle C, Hungerer S. Factitious disorders in everyday clinical practice. *Deutsches Ärzteblatt International*. 2020;117(26):452.
26. UK NGC. Attention deficit hyperactivity disorder: diagnosis and management. 2018.
27. Resmark G, Herpertz S, Herpertz-Dahlmann B, Zeeck A. Treatment of anorexia nervosa—new evidence-based guidelines. *Journal of clinical medicine*. 2019;8(2):153.
28. Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. *Bmj*. 2019;367.
29. Magierski R, Sobow T, Schwertner E, Religa D. Pharmacotherapy of Behavioral and Psychological

- Symptoms of Dementia: State of the Art and Future Progress. *Front Pharmacol* [Internet]. 2020 Jul 31:11.
30. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet*. 2020;396(10248):413-46.
31. Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer's disease: current and future pharmacotherapy options. *Journal of Alzheimer's disease*. 2019;67(3):779-94.
32. Fe'li SN, Ardekani SMY, Fallahzadeh H, Dehghani A. Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics. *Medical Journal of the Islamic Republic of Iran*. 2019;33:97.
33. Lisoway AJ, Chen CC, Zai CC, Tiwari AK, Kennedy JL. Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment. *Schizophrenia Research*. 2021;232:112-24.
34. Gowda GS, Isaac MK. Models of Care of Schizophrenia in the Community—An International Perspective. *Current psychiatry reports*. 2022:1-8.
35. Shamabadi A, Ahmadzade A, Aqamolaei A, Mortazavi SH, Hasanzadeh A, Akhondzadeh S. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials. *Iranian Journal of Psychiatry*. 2022;17(3):320-40.
36. Mas M, García-Vicente JA, Estrada-Gelonch A, Pérez-Mañá C, Papaseit E, Torrens M, et al. Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence. *Journal of Clinical Medicine*. 2022;11(14):4038.
37. Lewis C, Roberts NP, Andrew M, Starling E, Bisson JI. Psychological therapies for post-traumatic stress disorder in adults: Systematic review and meta-analysis. *European journal of psychotraumatology*. 2020;11(1):1729633.
38. Bonde JPE, Jensen JH, Smid GE, Flachs EM, Elklit A, Mors O, et al. Time course of symptoms in posttraumatic stress disorder with delayed expression: A systematic review. *Acta Psychiatrica Scandinavica*. 2022;145(2):116-31.
39. Jelinek L, Voderholzer U, Moritz S, Carsten HP, Riesel A, Miegel F. When a nightmare comes true: Change in obsessive-compulsive disorder over the first months of the COVID-19 pandemic. *Journal of anxiety disorders*. 2021;84:102493.
40. Chawla N, Anothaisintawee T, Charoenrungrueangchai K, Thaipisuttikul P, McKay GJ, Attia J, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network

meta-analysis of randomised controlled trials. *bmj*. 2022;376.

41. Nezgovorova V, Reid J, Fineberg N, Hollander E. Optimizing first line treatments for adults with OCD. *Comprehensive Psychiatry*. 2022;152305.

42. Mehta R, Giri S, Mallick BN. REM sleep loss–induced elevated noradrenaline could predispose an individual to psychosomatic disorders: a review focused on proposal for prediction, prevention, and personalized treatment. *EPMA Journal*. 2020;11(4):529-49.

43. Enck P, Klosterhalfen S. Placebo responses and placebo effects in functional gastrointestinal disorders. *Frontiers in Psychiatry*. 2020;11:797.

44. Masoomi M, Gholamian F, Sharifi V, Shadloo B. Self-immolation among women in Iran: A narrative review. *Iranian Journal of Psychiatry and Behavioral Sciences*. 2020;14(4).

45. Shahini N, Talaei A, Salimi Z, Adinepour Sarab M, Gholamzad S, Teimouri A, et al. Temperament and character traits in substance use disorder in Iran: a case control study. *BMC psychology*. 2021;9(1):1-8.

46. van Oostveen WM, de Lange EC. Imaging techniques in Alzheimer’s disease: a review of applications in early diagnosis and longitudinal monitoring. *International journal of molecular sciences*. 2021;22(4):2110.

47. Pressman PS, Matlock D, Ducharme S. Distinguishing Behavioral Variant Frontotemporal Dementia from primary psychiatric disorders: A review of recently published consensus recommendations from the Neuropsychiatric International Consortium for Frontotemporal Dementia. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 2021;33(2):152-6.

48. Taquet M, Sillett R, Zhu L, Mendel J, Campilison I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. *The Lancet Psychiatry*. 2022.

49. Jobehdar MM, Razaghi E, Haghdoost AA, Baleshzar A, Khoshnood K, Ghasemzadeh MR, et al. Factors That Influence the Effectiveness of Primary Prevention of Substance Use: A Review of Reviews. *Iranian Journal of Psychiatry and Behavioral Sciences*. 2021;15(4).

50. Reynolds 3rd CF, Jeste DV, Sachdev PS, Blazer DG. Mental health care for older adults: recent advances and new directions in clinical practice and research. *World Psychiatry*. 2022;21(3):336-63

